Aytu Biopharma grants 25,000 restricted shares to CFO
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AYTU BioPharma’s Chief Financial Officer, Ryan J. Selhorn, received a grant of 25,000 shares of restricted common stock on July 28, 2026. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments beginning October 28, 2027. Following this award, he directly holds 74,743 shares of common stock. The award is a grant/award acquisition rather than a market purchase and was not made under a Rule 10b5-1 trading plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 25,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.
Key Figures
Key Terms
restricted stock financial
vesting financial
quarterly installments financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AYTU’s CFO report in this Form 4?
Was the AYTU CFO’s restricted stock grant made under a Rule 10b5-1 plan?
What type of transaction does AYTU’s latest Form 4 for the CFO report?
AI-generated analysis. How Rhea-AI works. Not financial advice.